SEC Form 4 · accession 0001179110-18-001354
Esperion Therapeutics, Inc. · ESPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy M Mayleben
Officer — President & CEO · Director
Period of report
Jan 31, 2018
Accepted (ET)
Feb 1, 2018 · 5:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001434868
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 31, 2018 | M | 1,939 | $1.05 | A | 43,553 | D | |
| Common Stock | Jan 31, 2018 | M | 2,610 | $1.26 | A | 46,163 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.05 | Jan 31, 2018 | M | 1,939 | D | — | Jun 1, 2018 | Common Stock | 1,939 | 0 | D |
| Stock Option (right to buy)F1 | $1.26 | Jan 31, 2018 | M | 2,610 | D | — | Apr 2, 2020 | Common Stock | 2,610 | 0 | D |
Explanation of responses
- F1The options are fully vested as of the date hereof.